logo-ahplogo-ahplogo-ahplogo-ahp
  • Home
  • Firm
    • About Us
    • Careers
  • Solutions
      • Banking & Finance
      • Capital Markets
      • Competition Law
      • Debt & Corporate Restructuring
      • Dispute Resolution
      • Energy, Oil & Gas
      • Foreign Direct Investment
      • Fraud & Forensics Investigation
      • Intellectual Property
      • Islamic Finance
      • Labor Law
      • Mergers & Acquisitions
      • Projects & Natural Resources
      • Real Estate & Property
      • Shipping & Aviation
      • Tax & Customs Services
      • Telecommunications & Media
  • Members
  • Events
    • News & Insights
  • Rajah Tann Asia
✕
            No results See all results

            Rajah & Tann Asia Member Firms, Members of Lifesciences Asia-Pacific Network (LAN), Contribute to the Singapore and Indonesia Chapters of Comparative Study: Patent Linkage Systems in APAC


            Two member firms of Rajah & Tann Asia, Rajah & Tann Singapore and Assegaf Hamzah & Partners (“AHP“), are members of the Lifesciences Asia-Pacific Network (“LAN“) which was established for the Lifesciences sector to support and guide clients on all their legal and regulatory needs in the Asia-Pacific region. LAN’s members include other leading and largest law firms in the region, such as Atsumi & Sakai in Japan, Chen & Lin in Taiwan, CMS in China and Hong Kong, Corrs Chambers Westgarth in Australia, Khaitan & Co in India, Tilleke & Gibbins in Thailand and Vietnam, and Yulchon LLC in Korea.

            Rajah & Tann Singapore and AHP have recently contributed to the Singapore and Indonesia chapters of Comparative Study: Patent Linkage Systems in APAC, a comparative article produced by LAN on the Patent Linkage System across the Asia-Pacific region. Drug patent disputes prior to the planned launch of generic drugs have long been a challenge. On one hand, innovator drug companies face various challenges in the manufacture of drugs, such as the size of investments to be injected, long lead times, high risks of failure, and the difficulty of achieving innovations in the drug research and development process. On the other hand, generic drug companies have to contend with issues relating to patent protection policies that contribute to prolonged market domination of innovator drugs. As a result, tension arises between the affected innovator drug companies and generic drug companies. A patent linkage system provides for an early resolution of drug patent disputes and mitigation of potential infringement risks prior to the marketing of generic drugs. It aims to balance the interests of innovator drug companies and generic drug companies.

            The article provides an overview of the patent linkage systems in these Asia-Pacific countries: Australia, China, India, Indonesia, Japan, Korea, Singapore, Thailand and Vietnam. Lau Kok Keng (Head, Intellectual Property, Sports and Gaming, Rajah & Tann Singapore) and Eko Basyuni (Partner, AHP) authored the Singapore and Indonesia chapters, respectively, of the article.

            To read the full article with its annexes, please click here. Find out more about Rajah & Tann Singapore’s Intellectual Property practice here, and AHP’s Intellectual Property practice here.

             

            More Articles

            • PPSK Law and The Changing Landscape of Indonesia’s Capital Market Sector
              March 21, 2023
            • Does the New Regulation on Pre-Investigation Tax Audit Improve Certainty for Taxpayers?
              March 20, 2023
            • OJK Announced Guidelines to Implement Offerings Classified as Non-Public Offerings
              February 7, 2023
            • Regional Trade Highlights 2022
              January 30, 2023
            • Indonesia Expands Its Anti-Tax-Avoidance Measures: A Development to be Aware of in Tax Planning and Compliance
              January 27, 2023
            • Dissecting the Amendment to the Omnibus Law: Which Sectors are Affected and How?
              January 20, 2023
            • A New Rule Requires Importers of Software or Other Digital Products via Electronic Transmission to Fulfil Customs Obligations
              January 16, 2023
            • Rajah & Tann Asia Member Firms, Members of Lifesciences Asia-Pacific Network (LAN), Contribute to the Singapore and Indonesia Chapters of Comparative Study: Patent Linkage Systems in APAC
              January 13, 2023
            • Indonesia’s New Criminal Code Introduces Corporate Crime
              January 4, 2023
            • A Practical Guide to Getting Your Organisation PDP Law-Ready
              December 1, 2022
            By Practice Area
            • Projects & Energy
            • Technology Media & Telecommunications
            • Intellectual Property
            • Real Property
            • Banking & Finance
            • Capital Markets
            • Competition
            • Mergers & Acquisitions
            • Dispute Resolution
            • Tax and Customs

            Jakarta Office

            Capital Place, Level 36 & 37
            Jalan Jenderal Gatot Subroto Kav. 18
            Jakarta 12710,
            Indonesia

            Phone: +62 21 2555 7800
            Fax: +62 21 2555 7899
            Email: info@ahp.id


            Subcribe

            Surabaya Office

            Pakuwon Center, Superblok Tunjungan City
            Lantai 11, Unit 08
            Jalan Embong Malang No. 1, 3, 5,
            Surabaya 60261
            Indonesia

            Phone: +62 31 5116 4550
            Fax: +62 31 5116 4560

            Assegaf Hamzah & Partners


            © 2001 - 2022 Assegaf Hamzah & Partners. All rights reserved.

            Rajah & Tann Asia is a network of legal practices based in Asia.

            Member firms are independently constituted and regulated in accordance with relevant local legal requirements. Services provided by a member firm are governed by the terms of engagement between the member firm and the client.

            This website is solely intended to provide general information and does not provide any advice or create any relationship, whether legally binding or otherwise. Rajah & Tann Asia and its member firms do not accept, and fully disclaim, responsibility for any loss or damage which may result from accessing or relying on this website.